Update on morbidity and mortality in systemic sclerosis–related interstitial lung disease
Journal of Scleroderma and Related Disorders · 2021-02 · 6 (1) · 11-20
DOI: 10.1177/2397198320915042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Scleroderma and Related Disorders, online erschienen am 22.05.2020. Verfasst von Elizabeth R Volkmann und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, USA. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, Rheumatology Research Foundation.
Abstract (Originalsprache)
Contemporary studies of systemic sclerosis consistently demonstrate that interstitial lung disease is a leading cause of disease-related death. This review summarizes morbidity and mortality outcomes in systemic sclerosis-related interstitial lung disease patients from high-quality observational and interventional studies over the last 50 years. The data presented suggest a trend for improved morbidity and mortality outcomes among present day systemic sclerosis–associated interstitial lung disease patients. Specifically, systemic sclerosis–associated interstitial lung disease patients appear to be living longer from the time of the initial diagnosis. Despite improved survival, the number one cause of death for most systemic sclerosis–associated interstitial lung disease patients remains respiratory failure from interstitial lung disease. This review describes the most important demographic, clinical, and biological factors, which affect mortality in systemic sclerosis–associated interstitial lung disease, and could be used to help stratify patients for closer monitoring and more aggressive initial treatment. The review concludes with an overview of future research needed to (1) understand how to personalize the care of systemic sclerosis–associated interstitial lung disease patients to improve morbidity and mortality outcomes; and (2) investigate whether novel therapeutic interventions (e.g. anti-fibrotics, hematopoietic stem cell transplantation) offer any meaningful long-term survival advantage over the current standard of care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, USA.
- University of Colorado School of Medicine, Denver, USA.
Förderung
- NHLBI NIH HHS
- Rheumatology Research Foundation
Zitieren
APA
Volkmann, E. R., & Fischer, A. (2021). Update on morbidity and mortality in systemic sclerosis–related interstitial lung disease. Journal of Scleroderma and Related Disorders, 6(1), 11-20. https://doi.org/10.1177/2397198320915042
Vancouver
Volkmann ER, Fischer A. Update on morbidity and mortality in systemic sclerosis–related interstitial lung disease. Journal of Scleroderma and Related Disorders. 2021;6(1):11-20. doi:10.1177/2397198320915042
BibTeX
@article{Volkmann2021,
author = {Volkmann, Elizabeth R and Fischer, Aryeh},
title = {Update on morbidity and mortality in systemic sclerosis–related interstitial lung disease},
journal = {Journal of Scleroderma and Related Disorders},
year = {2021},
volume = {6},
number = {1},
pages = {11--20},
doi = {10.1177/2397198320915042}
}
EUVIMED